Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Other Working Capital Changes: 2019-2024

Historic Other Working Capital Changes for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Dec 2024 value amounting to $7.0 million.

  • Tarsus Pharmaceuticals' Other Working Capital Changes fell 794.34% to -$8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.2 million, marking a year-over-year increase of 1103.14%. This contributed to the annual value of $7.0 million for FY2024, which is 142.96% up from last year.
  • As of FY2024, Tarsus Pharmaceuticals' Other Working Capital Changes stood at $7.0 million, which was up 142.96% from $2.9 million recorded in FY2023.
  • In the past 5 years, Tarsus Pharmaceuticals' Other Working Capital Changes registered a high of $7.0 million during FY2024, and its lowest value of $721,000 during FY2022.
  • Moreover, its 3-year median value for Other Working Capital Changes was $2.9 million (2023), whereas its average is $3.5 million.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Other Working Capital Changes skyrocketed by 13,588.89% in 2020, and later crashed by 64.71% in 2022.
  • Yearly analysis of 5 years shows Tarsus Pharmaceuticals' Other Working Capital Changes stood at $2.5 million in 2020, then fell by 17.09% to $2.0 million in 2021, then tumbled by 64.71% to $721,000 in 2022, then spiked by 300.69% to $2.9 million in 2023, then spiked by 142.96% to $7.0 million in 2024.